stella
beta
Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinical Practice Among Chinese Patients — Stella
Home
/
Immune Related Adverse Events
/
View on ClinicalTrials.gov
Recruiting
Back to Immune Related Adverse Events trials
Trial locations
(1 site)
China
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing Municipality